ZA202301784B - Crf2 receptor agonists and their use in therapy - Google Patents

Crf2 receptor agonists and their use in therapy

Info

Publication number
ZA202301784B
ZA202301784B ZA2023/01784A ZA202301784A ZA202301784B ZA 202301784 B ZA202301784 B ZA 202301784B ZA 2023/01784 A ZA2023/01784 A ZA 2023/01784A ZA 202301784 A ZA202301784 A ZA 202301784A ZA 202301784 B ZA202301784 B ZA 202301784B
Authority
ZA
South Africa
Prior art keywords
therapy
receptor agonists
crf2
crf2 receptor
agonists
Prior art date
Application number
ZA2023/01784A
Other languages
English (en)
Inventor
Stephane Illiano
Laurence Lucats
Laetitia Ledein
Philippe Beauverger
Philip Janiak
Marie-Laure Ozoux
Nis Halland
Ziyu Li
Ralf Elvert
Andreas Evers
Elisabetta Bianchi
Alessia Santoprete
Daniela Roversi
Martina Tripepi
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ZA202301784B publication Critical patent/ZA202301784B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2023/01784A 2020-08-19 2023-02-14 Crf2 receptor agonists and their use in therapy ZA202301784B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20315387 2020-08-19
PCT/EP2021/072923 WO2022038179A1 (en) 2020-08-19 2021-08-18 Crf2 receptor agonists and their use in therapy

Publications (1)

Publication Number Publication Date
ZA202301784B true ZA202301784B (en) 2024-01-31

Family

ID=72615799

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/01784A ZA202301784B (en) 2020-08-19 2023-02-14 Crf2 receptor agonists and their use in therapy

Country Status (16)

Country Link
US (1) US12679878B2 (cg-RX-API-DMAC10.html)
EP (2) EP4199946B1 (cg-RX-API-DMAC10.html)
JP (2) JP7832927B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230051583A (cg-RX-API-DMAC10.html)
CN (1) CN116472053B (cg-RX-API-DMAC10.html)
AU (1) AU2021328673A1 (cg-RX-API-DMAC10.html)
CA (1) CA3192032A1 (cg-RX-API-DMAC10.html)
ES (1) ES2988026T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20240906T1 (cg-RX-API-DMAC10.html)
HU (1) HUE066991T2 (cg-RX-API-DMAC10.html)
IL (1) IL300464B1 (cg-RX-API-DMAC10.html)
IS (1) IS3063B (cg-RX-API-DMAC10.html)
MX (1) MX2023002087A (cg-RX-API-DMAC10.html)
PL (1) PL4199946T3 (cg-RX-API-DMAC10.html)
WO (1) WO2022038179A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202301784B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
EP4234574A1 (en) 2022-02-23 2023-08-30 Corteria Pharmaceuticals Crf2 receptor agonists and their use in therapy
KR20260089954A (ko) 2023-11-17 2026-06-16 구브라 에이/에스 hCRHR2 선택적 폴리펩타이드
TW202544027A (zh) * 2024-04-19 2025-11-16 美商紐羅克里生物科學有限公司 促皮質素釋放因子受體2(crfr2)促效劑
WO2025230248A1 (ko) * 2024-04-30 2025-11-06 한미약품 주식회사 Crf2 수용체 작용제와 그 아실화 결합체의 용도
WO2026064495A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026064486A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026139062A1 (zh) * 2024-12-26 2026-07-02 杭州先为达生物科技股份有限公司 促肾上腺皮质激素释放因子2受体激动剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114437A2 (en) * 2006-10-16 2009-11-11 ConjuChem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
WO2009022006A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
CN104356224A (zh) 2014-10-24 2015-02-18 杭州阿德莱诺泰制药技术有限公司 一种制备萨摩鲁泰的方法
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2019140030A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy

Also Published As

Publication number Publication date
JP2023541798A (ja) 2023-10-04
MX2023002087A (es) 2023-03-23
EP4435001A3 (en) 2024-10-09
IL300464A (en) 2023-04-01
HRP20240906T1 (hr) 2024-10-11
EP4199946C0 (en) 2024-06-05
IS3063B (is) 2025-06-15
CA3192032A1 (en) 2022-02-24
WO2022038179A1 (en) 2022-02-24
JP2026071260A (ja) 2026-04-28
JP7832927B2 (ja) 2026-03-18
PL4199946T3 (pl) 2024-08-19
HUE066991T2 (hu) 2024-09-28
US20250243255A1 (en) 2025-07-31
EP4435001A2 (en) 2024-09-25
CN116472053A (zh) 2023-07-21
IL300464B1 (en) 2026-07-01
CN116472053B (zh) 2026-07-31
EP4199946B1 (en) 2024-06-05
ES2988026T3 (es) 2024-11-19
US12679878B2 (en) 2026-07-14
EP4199946A1 (en) 2023-06-28
KR20230051583A (ko) 2023-04-18
AU2021328673A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
EP4435001A3 (en) Crf2 receptor agonists and their use in therapy
MX2022010011A (es) Inhibidores de prmt5 novedosos.
CR20230310A (es) Inhibidores de prmt5
ZA202403388B (en) Small molecules for treatement of cancer
SA521431209B1 (ar) مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
ZA202406196B (en) Crf2 receptor agonists and their use in therapy
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EP4616913A3 (en) Gcn2 inhibitors and uses thereof
MX2021006265A (es) Derivados de panteteina y usos de los mismos.
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
NZ608502A (en) Polypeptides that bind to human complement component c5
EP4327877A3 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
GEP20074197B (en) 5ht2c receptor modulators
IL308807B2 (en) Combination therapy for treating cancer
GEAP202516802A (en) Protac chimeric compound, preparation method thereof and use thereof
MX2023002522A (es) Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii.
MX2024002411A (es) Antagonista biológico que contiene anillos aromáticos, y método para su preparación y su uso.
CY1115908T1 (el) Υγρη συνταγοποιηση προϊοντος συζευξης g-csf
RU2011108486A (ru) ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ПЕПТИДА Wnt5-a ДЛЯ ЛЕЧЕНИЯ МЕЛАНОМЫ И РАКА ЖЕЛУДКА
ZA202205149B (en) Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
MX2024006684A (es) Inhibidores de hdac novedosos y uso terapéutico de estos.
EP4595996A3 (en) Treatment of lupus nephritis